Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.40 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.36 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.36 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.36 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26648780 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL283015 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL2920067 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL191366 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL28324857 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL172309 | 0.98 | — | — | |
| SCHEMBL170308 | 0.98 | — | — | |
| SCHEMBL162294 | 0.98 | — | — | |
| SCHEMBL28861034 | 0.95 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL28853863 | 0.95 | CYP2D6 (0.41) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110251680-B | Piperazine divinyl sulfonamide linker and preparation method and application thereof | 上海科技大学 | 2022-10-18 | — | — | CN | claimed |
| US-12637702-B2 | Process for preparing substituted imidazo[1,5-α]pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-121646112-A | Inhibiting deprotonation to realize high-crystallization CsxFA1-xPbI3Thin film and solar cell preparation method | 湖北大学 | 2026-03-10 | — | — | CN | disclosed |
| US-20230175026-A1 | Process for the Preparation of a Chiral Piperazine-2-carboxylic Acid | HOFFMANN-LA ROCHE INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115461333-A | Process for the preparation of chiral piperazine-2-carboxylic acid | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-110251680-B | Piperazine divinyl sulfonamide linker and preparation method and application thereof | 上海科技大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-108440507-B | Compound as apoptosis protein inhibitor and application thereof | 南京圣和药物研发有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022143610-A1 | NOVEL AMIDE PYRROLE COMPOUNDS AND USE THEREOF IN MEDICAMENTS | 广东东阳光药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685514-A | Novel amide pyrrole compound and application thereof in medicines | 广东东阳光药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-2044038-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Cornerstone Therapeutics Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| WO-2007146066-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CRITICAL THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20020128269-A1 | Substituted heterocyclic compounds for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-09-12 | — | — | US | disclosed |
| US-5945534-A | Process for the preparation of optically active piperazine-2-carboxylic acid derivatives | LONZA AG (CH) | 1999-08-31 | — | — | US | disclosed |
| US-5856485-A | RESOLUTION OF AN ENANTIOMORPH MIXTURE | LONZA AG (CH) | 1999-01-05 | — | — | US | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230175026-A1 | Process for the Preparation of a Chiral Piperazine-2-carboxylic Acid | HAVCR2, HCCS, DHPS | SLC6A1 451/4885GABRP 124/4885GABRD 242/4885 |
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, CYP2D6, CYP2B6 | SLC6A1 4550/4885GABRP 3229/4885GABRD 2125/4885 |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | HAVCR2, EIF2AK2, MAVS | SLC6A1 4246/4885GABRP 2782/4885GABRD 3699/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | SLC6A1 2026/4885GABRP 211/4885GABRD 333/4885 |
| US-20020128269-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCG2 | SLC6A1 1192/4885GABRP 1936/4885GABRD 1065/4885 |
| US-12637702-B2 | Process for preparing substituted imidazo[1,5-α]pyrazines | BCKDK, P4HB, DOHH | SLC6A1 1291/4885GABRP 526/4885GABRD 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.